Home » Stocks » CTDH

Cyclo Therapeutics Inc. (CTDH)

Stock Price: $0.0700 USD 0.0100 (16.67%)
Updated November 23, 12:58 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 11.90M
Revenue (ttm) 985,153
Net Income (ttm) -8.90M
Shares Out 169.98M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $0.0700
Previous Close $0.0600
Change ($) 0.0100
Change (%) 16.67%
Day's Open 0.0699
Day's Range 0.0650 - 0.0840
Day's Volume 242,521
52-Week Range 0.0499 - 0.3499

More Stats

Market Cap 11.90M
Enterprise Value 9.82M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 169.98M
Float 86.04M
EPS (basic) -0.07
EPS (diluted) -0.06
FCF / Share -0.05
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta -0.55
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 12.08
PB Ratio 6.62
Revenue 985,153
Operating Income -8.92M
Net Income -8.90M
Free Cash Flow -7.75M
Net Cash 2.08M
Net Cash / Share 0.01
Gross Margin 78.12%
Operating Margin -905.22%
Profit Margin -903.10%
FCF Margin -786.88%
ROA -111.53%
ROE -601.41%
ROIC 379.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$1.25*
Low
1.25
Current: $0.0700
High
1.25
Target: 1.25
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1.011.011.241.500.951.571.691.041.030.80
Revenue Growth-0.42%-18.28%-17.64%58.13%-39.36%-7.43%62.05%1.27%28.6%-
Gross Profit0.930.911.101.300.831.291.270.910.760.69
Operating Income-7.54-4.27-3.84-4.21-2.41-0.560.340.16-0.07-0.01
Net Income-7.53-4.26-3.83-4.22-2.55-0.590.200.07-0.10-0.04
Shares Outstanding10881.7672.0463.3556.2150.5437.1736.6835.8133.71
Earnings Per Share-0.07-0.05-0.05-0.07-0.05-0.010.010.01-0.01-0.01
EPS Growth------0%---
Operating Cash Flow-6.59-3.19-3.06-2.95-1.99-0.630.560.060.190.21
Capital Expenditures---0.92-0.42-0.17-0.15-0.17-0.55-0.44
Free Cash Flow-6.59-3.19-3.06-2.04-2.41-0.810.40-0.11-0.37-0.23
Cash & Equivalents2.822.251.310.991.842.380.270.020.130.11
Total Debt0.05---0.740.790.850.990.840.44
Net Cash / Debt2.772.251.310.991.101.59-0.58-0.96-0.71-0.33
Assets4.112.922.091.874.745.292.792.622.791.93
Liabilities3.181.930.940.341.000.920.991.071.370.53
Book Value0.940.991.151.533.754.371.801.551.421.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cyclo Therapeutics Inc.
Country United States
Employees 5
CEO Nathan Scott Fine

Stock Information

Ticker Symbol CTDH
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: CTDH

Description

Cyclo Therapeutics, a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.